GSK · Pharma and healthcare · one day
GSK (GSK): news on Saturday 14 November 2026
News from the 24 hours to Saturday morning, 14 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was dominated by a positive European regulatory opinion for GSK's Bexsero meningitis B booster, with further support from a Dutch court finding that BioNTech infringed a GSK vaccine patent. A pending Zantac settlement is a minor offsetting note.
What drove it
- Bexsero booster CHMP opinion
- vaccine patent ruling
- Zantac settlement
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Sun 8 Nov | +5.7 | 2 |
| Mon 9 Nov | −3.3 | 3 |
| Tue 10 Nov | +6.3 | 13 |
| Wed 11 Nov | +4.5 | 6 |
| Thu 12 Nov | +4.5 | 12 |
| Fri 13 Nov | +4.2 | 14 |
| Sat 14 Nov | +9.2 | 20 |
6 stories · 20 headlines · strongest first
Pharma and healthcare on 14 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| EU committee backs GSK's Bexsero meningitis B booster +9.711 headlines today · GSK received a positive CHMP opinion for a Bexsero booster dose for adolescents. | ||
| +10.0 | Favourable EU opinion for its meningitis vaccine booster. | |
| +10.0 | Favourable EU opinion for its meningitis B vaccine booster. | |
| +10.0 | Favourable European regulatory opinion for its meningitis vaccine booster. | |
| +10.0 | European regulator panel backs booster dose for its meningitis vaccine. | |
| +10.0 | Regulatory announcement of favourable opinion for vaccine booster. | |
| +10.0 | Company announces favourable regulatory opinion for its vaccine booster. | |
| +10.0 | Positive regulatory opinion for single-dose meningitis vaccine booster. | |
| +9.7 | EU panel backs adolescent booster for its meningitis B vaccine. | |
| +9.2 | Meningitis B booster advances toward European approval. | |
| +9.2 | Long-term data supports the case for the booster's labelling. | |
| +8.3 | EU panel supports its meningococcal vaccine for use in newborns. | |
| GSK wins UPC injunction against Pfizer and BioNTech +8.23 headlines today · 8 in all, since 12 November · Coverage notes a court upheld GSK's vaccine patent against Pfizer and BioNTech. | ||
| +9.2 | Court ruling backs GSK's vaccine patent against two rivals, strengthening its IP position. | |
| +6.7 | Dutch court found GSK patent infringed by BioNTech; mainly about BioNTech though. | |
| +6.7 | Court finding of infringement favours GSK; focus is on BioNTech deal. | |
| GSK market commentary +5.03 headlines today · Commentary pieces discuss GSK's medicines, vaccines and pipeline. | ||
| +5.8 | General positive overview of its pipeline progress. | |
| +5.8 | General positive overview of its medicines and vaccines progress. | |
| +3.3 | Vague commentary on share performance drivers, mildly supportive. | |
| Round-up pairs Aviva, Landsec and GSK vaccine news +6.71 headline today · A market round-up lists Aviva, Landsec and GSK's vaccine win. | ||
| +6.7 | Vaccine success listed as a market highlight among other stocks. | |
| GSK executive share purchases +5.01 headline today · A piece looks at GSK executive share purchases and recent gains. | ||
| +5.0 | Executive share buying alongside recent gains is mildly encouraging. | |
| GSK faces $2.2bn Zantac settlement −0.61 headline today · 3 in all, since 13 November · A piece discusses the Zantac settlement alongside GSK's patent wins. | ||
| +1.7 | Patent wins offset by pending Zantac settlement concerns. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.